Datascope Acquires Peripheral Vascular Stent Business of the Sorin Group

Datascope (Montvale, NJ, USA) has announced that it has exercised its option to acquire the peripheral vascular stent business of the Sorin Group (Milan, Italy).

The acquisition follows Datascope's successful experience as exclusive distributor of the Sorin peripheral stent product line in Europe, in which sales have grown rapidly since the product launch in January 2007. With the acquisition, Datascope will now have the opportunity to market the product line worldwide. Datascope estimates the worldwide market at $800 million annually, of which $200 million is in Europe, $500 million in the United States, and $40 million in Japan. As part of the acquisition, Datascope has also received worldwide rights to use Carbofilm technology and other intellectual property used in Sorin's vascular peripheral products, which are used by vascular surgeons and interventional radiologists for the treatment of peripheral arterial disease (PAD). The product line includes balloon-expandable and self-expanding stent systems, as well as balloon systems for use in percutaneous transluminal angioplasty (PTA).

"We look forward to integrating these new technologies, accelerating our product development and leveraging our capabilities in marketing, sales, clinical education, and training,” said Dr. Antonino Laudani, COO of Datascope. "We believe that our long presence and strength in the cardiovascular call point, as well as our commitment to innovation, will enable us to sustain a continuous growth of peripheral stent sales in the next years.”

We are delighted to have found a strategic partner for this business as capable as Datascope, of continuing and expanding the technological leadership and awareness in the interventional field,” said Andre-Michel Ballester, CEO of the Sorin Group. "Datascope's sales and marketing acumen combined with Sorin's technological and intellectual property platform is a winning combination for this business.”

The worldwide market for peripheral stents and PTA is expected to grow to over one billion U.S. dollars by 2012 due to an increase in diagnostic procedures, the demographics of the aging population and the higher incidence of diabetes, high blood pressure, obesity, and hypercholesterolemia, all leading causes of PAD.


Related Links:
Datascope
Sorin Group